Project Grant R01GM160762
- The National Institute of General Medical Sciences awarded the University of Texas at Austin $771,265 on September 15, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct structural and functional imaging of macromolecular machines involved in gene regulation using cryo-electron microscopy. The research encompasses three principal investigative avenues: mechanisms of RNA-guided CRISPR-Cas surveillance, methods to determine structures of human protein...
- The National Institute of General Medical Sciences awarded the University of Texas at Austin $270,208 on April 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct research on molecular mechanisms and developmental control of PAR polarity in animal embryos. The research resolves the network of protein-protein interactions that supports animal cell polarity and explores how this network responds to developmental signals. The work centers on an...
- The National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health within the Department of Health and Human Services, awarded the University of Texas at Austin $485,765 on August 15, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) for a Project Grant (R35GM161701) investigating the interactions between homologous recombination and non-homologous end joining pathways in double-strand break repair in human cells. The research...
- The National Institute of General Medical Sciences awarded The University of Texas Health Science Center at San Antonio $433,125 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research into the spatiotemporal regulation of DNA metabolism pathways. The project examines how homologous recombination proteins are selectively activated and deactivated at DNA lesions and replication fork structures, with particular focus on tyrosine...
- The National Institute of General Medical Sciences awarded the University of Texas at Austin $386,811 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop synthetic platforms for studying multivalent molecular recognition and communication. The funded research, led by the Callmann Lab, will create programmable polymeric scaffolds that isolate and systematically test individual variables—density, stereochemistry, topology, and...
- The National Institute of General Medical Sciences awarded $420,476 to the University of Texas Health Science Center at Houston on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support structural and mechanistic studies of eukaryotic gene transcription regulation. The recipient will conduct five years of integrated structural and molecular biology research investigating how the human CDK8 kinase module (comprising MED13, MED12, CDK8, and CYCC)...
- The National Institute of General Medical Sciences awarded University of Texas at Austin $434,480 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to elucidate the mechanisms of mitochondrial DNA heteroplasmy quality control. The project investigates how mitochondrial genomes maintain fidelity when both wild-type and mutant mtDNA coexist (heteroplasmy), and how tissue-specific thresholds govern mitochondrial function. The research leverages...
- The National Institute of General Medical Sciences awarded the University of Texas at Austin $429,650 on April 6, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate the interplay between cellular metabolism, chromatin regulation, and transcriptional control in ethylene signaling and stress responses in Arabidopsis. The research explores how chromatin-modifying enzymes utilize metabolic cofactors to influence histone modifications, nucleosome structure,...
- The National Institute of General Medical Sciences, a component of the Department of Health and Human Services, awarded $440,465 to the Massachusetts Institute of Technology on July 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop biophysical models of genome folding and function. Over the five-year performance period ending February 28, 2031, the award funds research into chromosome architecture and the mechanisms that shape it—motor-driven loop...
- The National Institute of General Medical Sciences awarded The University of Texas Southwestern Medical Center $556,694 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support structural and functional analysis of ciliary complexes, with work performed in Dallas, Texas through March 31, 2031. The award funds an integrated research program combining structural cell biology, disease-focused analysis, and technical innovation to advance...
The National Institute of General Medical Sciences awarded the University of Texas at Austin $491,703 in Project Grant funding on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on the molecular mechanisms of cohesin-mediated three-dimensional genome organization. The recipient will conduct mechanistic studies of how the cohesin complex, the architectural protein CTCF, its unloading factor WAPL, and regulatory RNAs collaborate to establish and remodel DNA loops that organize genetic information in space and time. The work encompasses three integrated aims: establishing biophysical rules governing how CTCF integrates DNA and RNA binding to specify loop boundaries through massively parallel profiling; reconstituting and directly visualizing CTCF-RNA cluster recruitment of cohesin and force-resistant loop formation at the single-molecule level; and determining the mechanism by which WAPL antagonizes CTCF-RNA clusters to disassemble loops. Mechanistic insights and protein variants from in vitro studies will be validated in mouse embryonic stem cells. The award supports fundamental research addressing how mutations in cohesin subunits lead to developmental disorders and cancers, with the long-term goal of defining molecular mechanisms underlying dynamic genome organization to maintain human health. Work will be performed in Austin, Texas, with a period of performance from September 1, 2026, through August 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $491.7k | 7/30/26 |